Veracyte saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 80 to 84.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or better RS Rating as they launch their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
While Veracyte is not near an ideal buy point right now, see if it goes on to form and break out from a proper consolidation.
Veracyte showed 71% EPS growth in its most recent report. Revenue rose 21%.
Veracyte holds the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
